Open AccessDramatic response of aneurysmal bone cyst to denosumab: Case report and literature review
Author(s) -
Fadavi Pedram,
Arefpour Amir Mohammad,
Hariri Ramyar,
Vasheghani Maryam,
Garousi Maryam,
TaghizadehHesary Farzad
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.4993
Subject(s) - denosumab , medicine , rankl , aneurysmal bone cyst , monoclonal antibody , cytokine , monoclonal , rank ligand , activator (genetics) , receptor , antibody , pathology , immunology , osteoporosis , lesion
Abstract Denosumab, a monoclonal antibody that specifically targets cytokine receptor activator of nuclear factor‐kappa B ligand (RANKL), is a potentially viable option in resistant aneurysmal bone cysts.